Beaumont G
J Int Med Res. 1977;5 Suppl 5:116-23.
In a large, open, multicentre trial, conducted in general practice, 765 patients suffering from agoraphobia or social phobias were treated with clomipramine (Anafranil, Geigy Pharmaceuticals). Four hundred and eight patients completed a twelve-week course of treatment. Of 285 withdrawals, 139 were due to side-effects. Good results were obtained on all measures of phobias in those patients who completed the study, the improvements being of the order of 70-80%, and over 50% of patients being symptom-free.
在一项在全科医疗中开展的大型、开放性、多中心试验中，765名患有广场恐惧症或社交恐惧症的患者接受了氯米帕明（安拿芬尼，嘉基制药公司）治疗。408名患者完成了为期12周的治疗疗程。在285名退出治疗的患者中，139名是由于副作用。完成研究的患者在所有恐惧症测量指标上均取得了良好效果，改善程度约为70%-80%，超过50%的患者症状消失。
